Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine and Pazopanib
Sponsor: Washington University School of Medicine
Not yet recruiting - verified March 2010
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Capecitabine; Drug: Cetuximab; Drug: Everolimus
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified October 2009
Condition: Pancreatic Adenocarcinoma
Interventions: Device: Gemcitabine + regional hyperthermia; Drug: Gemcitabine
Sponsors: Klinikum der Universitaet Muenchen, Grosshadern; European Society for Hyperthermic Oncology; Institute for Medical Informatics, Biometry and Epidemiology, Munich; ClinAssess GmbH, Leverkusen, Germany
Not yet recruiting - verified February 2010
Condition: Advanced Pancreatic Cancer
Intervention:
Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Not yet recruiting - verified February 2010
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Not yet recruiting - verified February 2010
Conditions: Pancreatic Cancer Stage II; Pancreatic Cancer Stage III
Interventions: Drug: Neoadjuvant gemcitabine, capecitabine, and docetaxel; Drug: Gemcitabine, capecitabine, docetaxel followed by radiotherapy
Sponsor: Columbia University
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: Hedgehog antagonist GDC-0449; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Drug: nelfinavir mesylate; Radiation: stereotactic body radiation therapy; Radiation: hypofractionated radiation therapy; Procedure: therapeutic conventional surgery; Other: pharmacological study; Genetic: polymorphism analysis; Other: pharmacogenomic studies; Genetic: protein expression analysis
Sponsor: University of Nebraska
Recruiting - verified February 2010
Conditions: Pancreatic Cancer; Colorectal Cancer
Intervention: Biological: Cancer macrobead placement in abdominal cavity
Sponsor: The Rogosin Institute
Not yet recruiting - verified February 2010
Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours
Intervention: Drug: olaparib
Sponsor: AstraZeneca
Recruiting - verified March 2010
Conditions: Pancreatic Cancer; Liver Cancer; Lung Cancer
Intervention: Procedure: MR Imaging
Sponsors: Stanford University; American Association of Physicists in Medicine
Recruiting - verified February 2010
Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsor: Pharmacyclics
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Advanced Pancreatic Cancer
Intervention: Drug: Tarceva, Gemcitabine, Nab-Paclitaxel
Sponsors: OSI Pharmaceuticals; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified February 2010
Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Sorafenib and Everolimus
Sponsors: Roswell Park Cancer Institute; Novartis; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified March 2010
Conditions: Kidney Cancer; Head and Neck Cancer; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Esophageal Cancer; Gliomas
Intervention: Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Conditions: Non-small Cell Lung Cancer; Pancreatic Cancer; Solid Tumors
Intervention: Drug: GSK1120212 plus everolimus
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Neoplasms
Interventions: Drug: RG1507; Drug: RAD001
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Primary Sclerosing Cholangitis; Trisomy 7; Cholangiocarcinoma; Chemoprevention
Intervention: Drug: Erlotinib (Tarceva)
Sponsors: Mayo Clinic; Genentech
Recruiting - verified February 2010
Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified February 2010
Condition: Refractory Solid Tumors
Intervention: Drug: AVN944
Sponsor: National Cancer Institute (NCI)
Completed - verified March 2010
Conditions: Breast Cancer; Glioma; Hepatocellular Cancer; Squamous Cell Lung Cancer; Pancreatic Cancer; Colon Cancer; Prostate Cancer
Intervention: Biological: Autologous Natural Killer / Natural Killer T Cell Immunotherapy
Sponsor: Envita Medical Center, Inc.
Suspended - verified February 2010
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: erlotinib [Tarceva]; Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Metastatic Pancreatic Carcinoma
Interventions: Radiation: tumoral irradiation; Biological: Dendritic cell vaccination; Biological: Additional cycles
Sponsor: University of Michigan Cancer Center
Suspended - verified February 2010
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Conditions: Pancreatic Neoplasms; Melanoma; Colorectal Neoplasms
Intervention: Drug: AP 12009
Sponsor: Antisense Pharma
Recruiting - verified February 2010
Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618; Drug: Gemcitabine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: Ipilimumab; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified February 2010
Condition: Non Functioning Entero-Pancreatic Endocrine Tumour
Intervention: Drug: lanreotide
Sponsor: Ipsen
Enrolling by invitation - verified February 2010
Condition: Gastrointestinal Cancer
Interventions: Behavioral: Questionnaire; Other: Interview
Sponsor: M.D. Anderson Cancer Center
Completed - verified February 2010
Conditions: Fibrocystic Disease of Breast; Breast Cancer
Intervention: Device: Digital Breast Tomosynthesis
Sponsor: Washington University School of Medicine
Enrolling by invitation - verified February 2010
Conditions: Cancer; Solid Tumor; Lymphoma
Interventions: Biological: 18F-FLT; Biological: 18F-FLT
Sponsor: Alberta Health Services
Not yet recruiting - verified December 2008
Conditions: Cancer; Non-small Cell Lung Cancer
Interventions: Drug: XL765; Drug: erlotinib
Sponsor: Exelixis
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Neoplasm
Interventions: Biological: monoclonal antibody; Drug: chemotherapy
Sponsors: Pfizer; University of Pennsylvania
Recruiting - verified March 2010
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Cancer; Cholangiocarcinoma; Liver
Intervention: Procedure: Liver Transplantation
Sponsor: University of Utah
Recruiting - verified March 2010
Condition: Pancreas Neoplasms
Interventions: Drug: Docetaxel; Drug: Oxaliplatin
Sponsor: University of Ulm
Recruiting - verified January 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Cholangiocarcinoma Cancer; Gallbladder Cancer; Pancreatic Cancer; Ampullary Cancer
Interventions: Drug: Gemcitabine and Docetaxel (Chemotherapy); Radiation: XRT at 5040 or 5400 cGy and 5FU (Radiation and Chemotherapy); Drug: Gemcitabine and Docetaxel (Chemotherapy)
Sponsor: Washington University School of Medicine
Recruiting - verified February 2010
Condition: Adenocarcinoma
Interventions: Drug: Gemcitabine; Drug: Placebo; Drug: Sorafenib
Sponsor: Johannes Gutenberg University Mainz
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Transplant
Intervention: Biological: Human papillomavirus quadrivalent vaccine
Sponsor: University of Alberta
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: RAD001; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; Novartis; OSI Pharmaceuticals
Active, not recruiting - verified February 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Adenocarcinoma of the Pancreas; Metastatic Pancreatic Cancer; Pancreatic Cancer
Interventions: Other: Placebo; Drug: AMG 479; Drug: AMG 655
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
All Categories ... by Medical Condition » ... Cancers » ... Pancreatic Cancer 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
